The content on this site is intended for healthcare professionals only
Prof Michael Seckl (Imperial College London, London, UK) introduces the upcoming meeting 'Future Horizons in Lung Cancer' coming to the Royal Society of Medicine in London on 1-2 September 2016.
But why should healthcare professionals be interested in this event? Prof Seckl explains what is unique and essential about this exciting meeting.
Prof Seckl and Prof Gordon McVie have jointly developed a programme covering the role of immunotherapy, new molecular target agents and resection for lung cancer, as well as offering over 20 internationally recognised speakers.
To register, go to the website
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Biomarkers, predictive and prognostic factors of resistance to immunotherapy
Hormonal receptor positive breast cancer adjuvant and metastatic indications
ASCO 2024: Lung cancer highlights
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Multiple myeloma in a resource constrained setting
Four chemo cycles given with durvalumab and tremelimumab optimise response and tumour shrinkage in patients with mNSCLC
LUMINANCE: Results support use of durvalumab and platinum-etoposide for extensive stage SCLC
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer
